Replies to post #1788 on Idenix Pharmaceuticals (IDIX)

[DewDiligence]

2007-2008 News Flow

[Removed Valtorcitabine item; added NVS’ R&D
presentation and the start of IDX-899 dosing.]


Sep 12 (tomorrow): NVS’ annual R&D presentation.

Oct 07: Start of dosing in IDX-899 phase-1 trial.

Nov 07: Data from selected Tyzeka post-marketing studies at AASLD conference.

Nov 07: 3Q07 financial results and CC.

End 2007: Seven-day viral-load data for IDX899 in treatment-naïve HIV.

End 2007: File IND for IDX102 or IDX184 2nd-generation HCV nucleoside analogs.

End 2007: Report on IDX899 interaction w/P450 in 4Q07

Feb 08: IDX899 data at CROI conference.

Mar 08: 4Q07 financial results and CC with 2008 financial guidance.

May 08: Expiration of NVS-IDIX standstill agreement.

End 2008: File IND for HCV non-nucleoside polymerase inhibitor.

End 2008: File IND for HCV protease inhibitor.